Curative Biosciences Stock Cash Flow From Operations
| CBDX Stock | USD 0.0001 0.00 0.00% |
Curative Biosciences fundamentals help investors to digest information that contributes to Curative Biosciences' financial success or failures. It also enables traders to predict the movement of Curative Pink Sheet. The fundamental analysis module provides a way to measure Curative Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Curative Biosciences pink sheet.
Curative |
Curative Biosciences Company Cash Flow From Operations Analysis
Curative Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Curative Biosciences Cash Flow From Operations | (12.8 K) |
Most of Curative Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Curative Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Curative Biosciences has (12,797) in Cash Flow From Operations. This is 100.0% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The cash flow from operations for all United States stocks is 100.0% higher than that of the company.
Curative Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Curative Biosciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Curative Biosciences could also be used in its relative valuation, which is a method of valuing Curative Biosciences by comparing valuation metrics of similar companies.Curative Biosciences is currently under evaluation in cash flow from operations category among its peers.
Curative Fundamentals
| Return On Asset | -38.44 | |||
| Current Valuation | 9.68 M | |||
| Shares Outstanding | 31.57 M | |||
| Shares Owned By Insiders | 76.24 % | |||
| EBITDA | (50.35 K) | |||
| Net Income | (53.2 K) | |||
| Cash And Equivalents | 982 | |||
| Total Debt | 156.45 K | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (12.8 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | 8.19 | |||
| Market Capitalization | 10.56 M | |||
| Total Asset | 2.27 K | |||
| Z Score | -32.4 | |||
| Net Asset | 2.27 K |
About Curative Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Curative Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curative Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curative Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Curative Pink Sheet Analysis
When running Curative Biosciences' price analysis, check to measure Curative Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biosciences is operating at the current time. Most of Curative Biosciences' value examination focuses on studying past and present price action to predict the probability of Curative Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biosciences' price. Additionally, you may evaluate how the addition of Curative Biosciences to your portfolios can decrease your overall portfolio volatility.